Aethon Therapeutics
New York
About Aethon Therapeutics
Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness. Aethon's unique anti-drug-peptide conjugate/MHC antibodies are intended to be employed in conjunction with TCI of RAS, EGFR, and other cancer-associated mutations.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $30.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2023)
- Website: aethontx.com
Industries & Categories
Biotechnology, Health Care, Product Research
Social Profiles
Canonical: https://fsome.com/organization/aethon-therapeutics-37962 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.